ANTELOPE – Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma - ANTELOPE

Charite Universitaetsmedizin Berlin KöR0 个研究点目标入组 136 人开始时间: 2023年5月2日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 136

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Patient has provided written informed consent, Adequate hepatic, renal and bone marrow function a)Hemoglobin = 8.0 g/dL b)Absolute neutrophil count = 1.5 x 109/L c)Platelets = 100 x 109/L d)Calculated creatine clearance = 50 mL/min as determined by the Cockgraft-Gault equation and/or creatine = 1,5x upper limit of normal (ULN) e)Serum bilirubin = 1.5 x institutional ULN f)AST/ ALT and alkaline phosphatase = 2.5 x ULN g)International normalized ratio (INR)/ Activated partial thromboplastin time (aPTT) =1.5 × ULN unless participant is receiving anticoagulant therapy as long as PTT is within therapeutic range of intended use of anticoagulants, The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations., Female patients who are considered as woman of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as up to 6 months after the last dose of study treatment. Male patients who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year during the treatment as well as at least 6 months after the last dose of IMP. Female patients who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile, see section 5.1.5) as well as azoospermic male patients do not require contraception, Patient* 18 years or older at time of signing the informed consent form, Histologically or cytologically confirmed metastatic stage IV non-squamous NSCLC, Negative local testing for TTF-1, Negative molecular testing for EGFR mutations and ALK rearrangements (tested locally), PD-L1 tumor proportion score (TPS) < 50%**, ECOG performance status = 1, Measurable lesions according to RECIST v1.1, Life expectancy = 12 weeks

排除标准

•Mixed histology (small-cell and non-small cell or non-squamous and squamous; patients exhibiting the latter expression pattern may be eligible if the non-squamous part predominates), Active or prior documented autoimmune or inflammatory disorders (including but not limited to diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis, or Wegener’s syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis). The following are exceptions to this criterion: a.Patients with vitiligo or alopecia b.Patients with hypothyroidism (e.g., following Hashimoto’s disease) stable on hormone replacement c.Patients with controlled Type I diabetes mellitus on an insulin regimen d.Any chronic skin condition that does not require systemic therapy e.Patients without active disease in the last 5 years may be included but only after consultation with the study physician, Current or prior use of immunosuppressive medication within 14 days before the first dose of atezolizumab/pembrolizumab. The following are exceptions to this criterion: a.Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection) b.Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent c.Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication), Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment, Live vaccine within 30 days prior to first dose of trial treatment, Known allergy or contraindication against to or hypersensitivity to any component of the chemotherapy regimen or to atezolizumab or pembrolizumab or any constituents of the products, Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the study., Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities., Patients having received: a.Systemic treatment for metastatic or locally advanced disease b.prior PD-1/PD-L1 immunotherapies (prior treatment with CD137 agonists or immune checkpoint blockade therapies, including, but not limited to, anti-cytotoxic T lymphocyte associated protein 4 [anti-CTLA-4], anti T cell immunoreceptor with Ig and tyrosine-based inhibition motif domains [anti-TIGIT], anti-PD-1 and anti-PD-L1 therapeutic antibodies), Symptomatic, neurologically unstable CNS metastases or requiring increasing doses of steroids to manage CNS symptoms within 2 weeks prior to study entry (maximal acceptable dose must be = 10 mg of prednisolone), Leptomeningeal disease, History of interstitial lung disease, Severe infection within 2 weeks prior to study entry. Clinical signs must have been resolved to CTCAE grade = 1, Active infection with hepatitis B or C virus (HBV, HCV), human immunodeficiency virus (HIV) or Mycobacterium tuberculosis, Known additional malignancies other than NSCLC, either untreated or having required active treatment within the past 3 years, with the exception of malignancies with a negligible risk of metastasis or death (e.g. 5-year OS rate >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in sit

研究者

发起方

Charite Universitaetsmedizin Berlin KöR

相似试验

招募中

2 期

“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”

2024-519514-31-00Consorzio Oncotech104

进行中（未招募）

1 期

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancer.Women with a diagnosis of non-metastatic high-risk invasive unilateral, HER2-positive breast cancer.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-000981-31-BEFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650

进行中（未招募）

1 期

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancer.

EUCTR2017-000981-31-ATFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650

进行中（未招募）

1 期

Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancerWomen with a diagnosis of non metastatic high-risk invasive unilateral, HER2-positive breast cancerMedDRA version: 20.0Level: LLTClassification code 10006283Term: Breast neoplasm malignant femaleSystem Organ Class: 100000004864

EUCTR2017-000981-31-ITFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650

进行中（未招募）

1 期

EUCTR2017-000981-31-ROFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650